Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Current Assets: 2009-2024

Historic Current Assets for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to $1.0 billion.

  • Madrigal Pharmaceuticals' Current Assets rose 26.61% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 26.61%. This contributed to the annual value of $1.0 billion for FY2024, which is 62.08% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Current Assets of $1.0 billion as of FY2024, which was up 62.08% from $637.3 million recorded in FY2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Current Assets peaked at $1.0 billion during FY2024, and registered a low of $271.7 million during FY2021.
  • For the 3-year period, Madrigal Pharmaceuticals' Current Assets averaged around $677.2 million, with its median value being $637.3 million (2023).
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Current Assets tumbled by 35.22% in 2020, and later skyrocketed by 76.35% in 2023.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Current Assets stood at $285.2 million in 2020, then dropped by 4.73% to $271.7 million in 2021, then soared by 33.01% to $361.4 million in 2022, then spiked by 76.35% to $637.3 million in 2023, then spiked by 62.08% to $1.0 billion in 2024.